Skip to main content

Carbetapentane Side Effects

Applies to carbetapentane: oral suspension extended release.

Warning

Do not use carbetapentane if you have used an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others.

Get emergency medical help if you have any of these signs of an allergic reaction while taking carbetapentane: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using carbetapentane and call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to carbetapentane: oral suspension extended release.

Gastrointestinal

Gastrointestinal side effects have included nausea and other gastrointestinal disturbances.[Ref]

Nervous system

Nervous system side effects have included dizziness and drowsiness. Other potential reactions include anxiety, disturbed coordination, euphoria, fatigue, headache, acute labyrinthitis, neuritis, paresthesias, tinnitus, and vertigo.[Ref]

Hypersensitivity

Hypersensitivity side effects have included pruritus, rash, and urticaria. Anaphylactic shock has been reported.[Ref]

Dermatologic

Dermatologic side effects have included photosensitivity. Rare cases of allergic exanthema have been associated with carbetapentane use.[Ref]

Hematologic

Hematologic side effects have included rare cases of leukopenia reported in patients receiving carbetapentane.[Ref]

References

1. Product Information. solotuss (carbetapentane). Hawthorn Pharmaceuticals. 2007.

2. Multum Information Services, Inc. Expert Review Panel

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.